Direct-to-consumer advertising

Identifies and assesses potential impacts of direct-to-consumer prescription drug advertising on health care delivery in Canada. Estimates the costs of these impacts.

Identifies and assesses potential impacts of direct-to-consumer prescription drug advertising on health care delivery in Canada. Estimates the costs of these impacts.

Analyzes why the issue of DTCA in Canada is of particular concern for women’s health.

Argues against the legalization of direct-to-consumer advertising of prescription drugs in Canada.

Examines the health risks associated with Diane-35, a drug to treat severe acne, yet marketed as a bill control pill.

Targets a recent ad campaign, entitled "Julie's Story," sponsored by Hoffman-LaRoche, makers of Xenical. Describes the side-effects of this drug, and presents a mock ad, entitled "Barbara's Story."

Looks are the debate surrounding direct-to-consumer drug advertisement and its potential impact on patient education.

Criticizes federal prescription drug regulation using Diane-35 (cyproterone acetate and ethinyl estradiol) as an example.

Discusses the health concerns for Diane-35, a combination product advertised as a birth control pill and acne medication. Looks at how this drug is advertised to both physicians and consumers.

Presents a social marketing poster outlining the cons of direct-to-consumer advertising of prescription drugs.